In this study, we show that both SDC1 and B-FN are involved in EOC progression and we hypothesize a possible employment of L19-IL2 and of the new anti-syndecan-1 46F2SIP (small immuno protein) antibody format in combined therapy to treat a human ovarian carcinoma model. Here, SDC1 is linked to ovarian carcinoma.